Please Wait
Applying Filters...
menu
    • menu

    Annual Sales of Erythropoietin EPO reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

    Client Email Product
    Renejix: CDMO with expertise in small molecule oral dosage, delivery tech, and multi-modality manufacturing.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Ribobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Erythropoietin EPO

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 9Epogen

    02 2Espo

    03 3NeoRecormon/Epogin

    04 1Procrit

    05 5Procrit/Eprex

    06 2Procrit/Eprex

    PharmaCompass
    Left Arrow
    Right Arrow
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : NeoRecormon/Epogin

    Epoetin Alfa

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : NeoRecormon/Epogin

    Switzerland
    arrow
    AAPS 2024
    Not Confirmed

    Roche

    Epoetin Alfa

    Main Therapeutic Indication : Hematology

    Currency : USD

    2019 Revenue in Millions : 270

    2018 Revenue in Millions : 297

    Growth (%) : -9

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Epogen

    Epoetin Alfa

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Epogen

    U.S.A
    arrow
    AAPS 2024
    Not Confirmed

    Amgen

    Epoetin Alfa

    Main Therapeutic Indication : Hematology

    Currency : USD

    2020 Revenue in Millions : 598

    2019 Revenue in Millions : 867

    Growth (%) : -31

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : NeoRecormon/Epogin

    Epoetin Alfa

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : NeoRecormon/Epogin

    Switzerland
    arrow
    AAPS 2024
    Not Confirmed

    Roche

    Epoetin Alfa

    Main Therapeutic Indication : Hematology

    Currency : USD

    2020 Revenue in Millions : 266

    2019 Revenue in Millions : 292

    Growth (%) : -9

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Procrit/Eprex

    Epoetin Alfa

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Procrit/Eprex

    U.S.A
    arrow
    AAPS 2024
    Not Confirmed

    Johnson & Johnson

    Epoetin Alfa

    Main Therapeutic Indication : Hematology

    Currency : USD

    2020 Revenue in Millions : 552

    2019 Revenue in Millions : 790

    Growth (%) : -30

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Epogen

    Epoetin Alfa

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Epogen

    U.S.A
    arrow
    AAPS 2024
    Not Confirmed

    Amgen

    Epoetin Alfa

    Main Therapeutic Indication : Hematology

    Currency : USD

    2021 Revenue in Millions : 521

    2020 Revenue in Millions : 598

    Growth (%) : -13

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Procrit/Eprex

    Epoetin Alfa

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Procrit/Eprex

    U.S.A
    arrow
    AAPS 2024
    Not Confirmed

    Johnson & Johnson

    Epoetin Alfa

    Main Therapeutic Indication : Hematology

    Currency : USD

    2021 Revenue in Millions : 479

    2020 Revenue in Millions : 552

    Growth (%) : -13

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Epogen

    Epoetin Alfa

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Epogen

    U.S.A
    arrow
    AAPS 2024
    Not Confirmed

    Amgen

    Epoetin Alfa

    Main Therapeutic Indication : Hematology

    Currency : USD

    2022 Revenue in Millions : 506

    2021 Revenue in Millions : 521

    Growth (%) : -3

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Epogen

    Epoetin Alfa

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Epogen

    U.S.A
    arrow
    AAPS 2024
    Not Confirmed

    Amgen

    Epoetin Alfa

    Main Therapeutic Indication : Blood Related Disorders

    Currency : USD

    2015 Revenue in Millions : 2,031

    2014 Revenue in Millions : 1,856

    Growth (%) : -9%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Procrit

    Epoetin Alfa

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Procrit

    U.S.A
    arrow
    AAPS 2024
    Not Confirmed

    Johnson & Johnson

    Epoetin Alfa

    Main Therapeutic Indication : Blood Related Disorders

    Currency : USD

    2014 Revenue in Millions : -9.20%

    2013 Revenue in Millions :

    Growth (%) :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Epogen

    Epoetin Alfa

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Epogen

    U.S.A
    arrow
    AAPS 2024
    Not Confirmed

    Amgen

    Epoetin Alfa

    Main Therapeutic Indication : Blood Disorders

    Currency : USD

    2017 Revenue in Millions : 1,096

    2016 Revenue in Millions : 1,282

    Growth (%) : -15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF